Thomas C. Harding

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer”.

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer

EBioMedicine(2020)10.1016/j.ebiom.2020.102988

N/A

0DataRank · unranked

38 citations

Reid Shaw, Franz X. Schaub, Isabella N. Stork, Kay E. Gurley, Caroline Bridgwater +11 more

Characterization of a RAD51C -Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.12.25.419978

N/A

0DataRank · unranked

2 citations

Cordelia D. McGehee, Ksenija Nesic, Cristina Correia, Taylor M. Weiskittel, Rebecca L. Kelly +25 more

Characterization of a RAD51C -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance

NAR Cancer(2021)10.1093/narcan/zcab028

N/A

0DataRank · unranked

37 citations

Cordelia D. McGehee, Ksenija Nesic, Cristina Correia, Taylor M. Weiskittel, Rebecca L. Kelly +28 more

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

medRxiv(2023)10.1101/2023.03.20.23287465

N/A

0DataRank · unranked

9 citations

John J. Krais, Cassandra J. Vandenberg, Yifan Wang, Pooja Patel, Kathy Q. Cai +30 more